Total submissions: 4
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Illumina Laboratory Services, |
RCV000337739 | SCV000478304 | uncertain significance | Upshaw-Schulman syndrome | 2016-06-14 | criteria provided, single submitter | clinical testing | |
Labcorp Genetics |
RCV002523745 | SCV003273064 | benign | not provided | 2023-09-19 | criteria provided, single submitter | clinical testing | |
Women's Health and Genetics/Laboratory Corporation of America, |
RCV003987523 | SCV004803305 | uncertain significance | not specified | 2024-01-12 | criteria provided, single submitter | clinical testing | Variant summary: ADAMTS13 c.539+7G>A alters a non-conserved nucleotide located close to a canonical splice site and therefore could affect mRNA splicing, leading to a significantly altered protein sequence. Consensus agreement among computational tools predict no significant impact on normal splicing. However, these predictions have yet to be confirmed by functional studies. The variant allele was found at a frequency of 0.00018 in 251070 control chromosomes (gnomAD). To our knowledge, no occurrence of c.539+7G>A in individuals affected with Thrombotic Thrombocytopenic Purpura and no experimental evidence demonstrating its impact on protein function have been reported. ClinVar contains an entry for this variant (Variation ID: 365536). Based on the evidence outlined above, the variant was classified as uncertain significance. |
Breakthrough Genomics, |
RCV002523745 | SCV005190556 | uncertain significance | not provided | criteria provided, single submitter | not provided |